Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | GALK1 | P51570 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645377 | 0.87 | MEN1 (0.53) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL9651248 | 0.87 | MEN1 (0.53) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL5660097 | 0.87 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL4023786 | 0.85 | TRPV1 (0.64) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL30114438 | 0.85 | TRPV1 (0.64) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL4028212 | 0.84 | TRPV1 (0.65) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL6630943 | 0.84 | TRPV1 (0.59) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL2315592 | 0.84 | KDM4E (0.67) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL30544195 | 0.84 | KDM4E (0.67) | MAPTKDM4EGALK1ATMALDH1A1 | |
| SCHEMBL17776532 | 0.83 | TRPV1 (0.62) | MAPTKDM4EGALK1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403842-B1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-06-29 | — | — | EP | claimed |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | claimed |
| US-12534484-B2 | Process for preparing dimeric phosphazene derived BrØnsted acids | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2026-01-27 | — | — | US | disclosed |
| EP-4200308-B1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-10 | — | — | EP | disclosed |
| US-20230406870-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| EP-4200308-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | Studiengesellschaft Kohle gGmbH (DE) | 2023-06-28 | — | — | EP | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-11345696-B2 | Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same | DREXEL UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022073803-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-04-14 | — | — | WO | disclosed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| EP-0518961-A1 | DERIVATIVES OF GLYCINAMIDE, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | MAPT 4673/4885KDM4E 4154/4885GALK1 1583/4885 |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | MAPT 4302/4885KDM4E 1442/4885GALK1 3241/4885 |
| US-20230406870-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | PHOSPHO1, BRPF1, BRD9 | MAPT 3338/4885KDM4E 3341/4885GALK1 1140/4885 |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | MAPT 4461/4885KDM4E 433/4885GALK1 78/4885 |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPT 4176/4885KDM4E 3677/4885GALK1 1746/4885 |
| US-12534484-B2 | Process for preparing dimeric phosphazene derived BrØnsted acids | HAT1, LBR, CD79B | MAPT 3245/4885KDM4E 2895/4885GALK1 3090/4885 |
| US-11345696-B2 | Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same | IL1RN, IL1R1, IL1B | MAPT 3088/4885KDM4E 2857/4885GALK1 2150/4885 |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STS, SUDS3, SF1 | MAPT 4525/4885KDM4E 2415/4885GALK1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.